- $1.79bn
- $1.87bn
- $109.79m
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: UroGen Pharma Expansion Of Oncology Pipeline Portfolio Through Acquisition Of Assets Relating To Oncolytic Virus Icvb-1042 From Iconovir Bio
Brief: Data From A Long-Term Follow-Up Study To The Olympus Trial Published In The Journal Of Urology
Brief: UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
Brief: Envision Trial Results Published In The Journal Of Urology Report 82.3% Duration Of Response 12 Months After Achieving Complete Response For UGN-102, Potentially First FDA-Approved Non-Surgical Treatment For LG-IR-NMIBC
Brokerages expect blockbuster sales for Urogen's bladder cancer drug candidate
Brief: UroGen Announces FDA Acceptance Of Its New Drug Application For UGN-102
Urogen Pharma falls on CFO appointment
Urogen Pharma falls on pricing stock offering
Brief: Urogen Prices Underwritten Public Offering Of 5 Mln Ordinary Shares At A Price To Public Of $17.50 Per Ordinary Share
Brief: Urogen Pharma Announces Commencement Of Public Offering Of Ordinary Shares And Pre-Funded Warrants
Brief: UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103
Brief: Urogen Pharma Received A Paragraph IV Certification Notice Letter From Teva Pharmaceuticals, Inc
Brief: Urogen Initiates Submission Of A Rolling NDA To The FDA For Ugn-102
Brief: Urogen Pharma Plans To Initiate Phase 3 Study In 2024
Brief: RA Capital Management, L.P. Reports 9.99% Passive Stake In Urogen Pharma As Of December 19
Brief: Following Pre-NDA Meeting With The FDA, Urogen Announces Rolling NDA Submission For Ugn-102 To Begin January 2024
Brief: UroGen Pharma Ltd Files For Offering Of Up To 12.6 Million Shares Of Common Stock By The Selling Shareholders - SEC Filing
Urogen rises on higher Q2 sales of its cancer drug